Creative Biolabs offers a series of lymphangiogenesis analysis services for our clients all over the world. We have integrated high-quality lymphangiogenesis analysis solutions that are based in America and span the entire development chain from design to validation. With our extensive experience and advanced platform, we have won a good reputation among our worldwide customers for successfully accomplishing many projects in this field.
Nowadays, lymphangiogenesis has proven its significant role in the regulation of cancer progression, metastasis, and prognosis. Much evidence has shown that understanding the mechanism of lymphatic vessel formation can provide meaningful data for guiding the new avenues for the development of cancer immunotherapy. Moreover, recent researchers have revealed that different kinds of tumor cells can also induce lymphangiogenesis in lymph nodes. Also, metastatic tumor cells further induce the growth of lymphatic vessels in sentinel lymph nodes, thus promoting further metastasis and diffusion. Therefore, a variety of lymphatic endothelial cell (LEC) markers, such as vascular endothelial growth factor C (VEGFC) and vascular endothelial growth factor D (VEGF-D), have been identified and widely used for the identification of lymphatic formations.
Fig.1 The currently known VEGFs and their receptors. (Al-Rawi, et al., 2005)
Lymphangiogenesis analysis has aroused much attention in the development of novel cancer immunotherapy. Currently, a well-mature, comprehensive platform has been generated by our labs. As a result, Creative Biolabs offers a full range of lymphangiogenesis analysis services to bring further progress in this field. Use of the published data and different kinds of in vivo and in vitro models, we have successfully provided numerous data for the understanding of lymphatic and blood vessel coordination growth and its impact on human diseases, especially cancer. Furthermore, we have integrated a flow cytometry-based quantification system of lymphatic and blood endothelial cells. For example, we have isolated LECs from lymphatic vessels or skins, followed by enzymatic digestion and flow cytometric sorting using specific LECs markers, validating several recently discovered LEC markers, like Prox-1, VEGFR-3, as well as podoplanin. Besides, some LEC markers, lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), and podoplanin, the expression has also been detected by using immunohistochemistry and H&E staining to study their roles in the lymphangiogenesis and progression of non-small-cell-lung-cancer (NSCLC) models.
Fig.2 Proposed model for VEGFC vax mechanism of action. (Sasso, et al., 2021)
In a recent study conducted by our labs, we used different drugs or agents, such as specific antibodies, soluble receptor constructs, and small molecule kinase inhibitors to block the VEGFR3 pathway in mouse colorectal cancer (CRC) models. The results suggest that these approaches can effectively inhibit tumor lymphangiogenesis and metastasis, and may also represent a new therapeutic approach in the clinic.
In addition, several melanoma cells from mice have been engineered to secrete VEGFC. After irradiating overexpression VEGFC tumor cells, they were rejected into tumor models and the data have demonstrated that these cells can activate a more robust and long-lasting immune response to recognize and kill the actual tumor cells, which holds great promise for the future of cancer immunotherapy.
Creative Biolabs is specialized in designing and performing high-quality custom lymphangiogenesis analysis services, with different formats or parameters, to satisfy any specific requirement at the most competitive price. For more detailed information, please feel free to contact us or directly sent us an inquiry.
References
For Research Use Only | Not For Clinical Use
Download our brochure